Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta‐analysis based on randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta‐analysis based on randomized controlled trials

Published:2021-09-20 Issue: Volume: Page:
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Wu Qian¹²,Liu Miaowen¹²,Fang Zige¹²^ORCID,Li Chenxi¹²,Zou Fang¹,Hu Lei¹,Zhang Wenxiong³^ORCID

Affiliation:

1. Department of Endocrinology The second affiliated hospital of Nanchang University Nanchang China

2. Jiangxi Medical College Nanchang University Nanchang China

3. Department of Cardio‐Thoracic Surgery The second affiliated hospital of Nanchang University Nanchang China

Funder

Natural Science Foundation of Jiangxi Province

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13521

Reference50 articles.

1. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas;Saeedi P;Diabetes Res Clin Pract,2019

2. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

4. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2

5. Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study;Pharmacoepidemiology and Drug Safety;2024-05

2. Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients;Diabetes & Metabolism Journal;2024-03-31

3. Evaluation of Efficacy and Safety of Empagliflozin in Bangladeshi Patients with Type 2 Diabetes Mellitus (EFFISAEM Study);Indian Journal of Endocrinology and Metabolism;2024-03-08

4. Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial;European Journal of Clinical Pharmacology;2023-10-28

5. Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?;Canadian Journal of Cardiology;2023-05